Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Holding DXCM?
Track your performance easily
DXCM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.34 - $142.00
Previous Close$80.24
Volume1.15M
Average Volume (3M)4.15M
Market Cap
$31.07B
Enterprise Value$32.98B
Total Cash (Recent Filing)$621.20M
Total Debt (Recent Filing)$2.53B
Price to Earnings (P/E)48.1
Beta0.84
Next Earnings
Feb 06, 2025EPS Estimate
$0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding390,595,390
10 Day Avg. Volume3,810,346
30 Day Avg. Volume4,150,457
Standard Deviation0.14
R-Squared0.17
Alpha0.00130
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)15.69
Price to Sales (P/S)7.91
Price to Cash Flow (P/CF)39.20
P/FCF Ratio85.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.34
Enterprise Value/Gross Profit14.41
Enterprise Value/Ebitda33.88
Forecast
1Y Price Target
$98.94Price Target Upside23.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Dexcom News
Bulls Say, Bears Say
Bulls Say
Product Launch And Market ExpansionDXCM launched new products like Stelo OTC, G7 in Australia, and Dexcom ONE+ in France, indicating strong product pipeline progress.
Regulatory And Market ApprovalHospital CGM Approval May Finally Be Here Soon; We See a $1B+ Incremental Opportunity.
Revenue Growth PotentialA new $1bn+ revenue opportunity now in.
Bears Say
Investor ConcernsSofter U.S. performance in the recent quarter heightens investor concerns about a slowing market, making it difficult to ease fears in the near-term.
Market Share LossDXCM lost additional market share in the DME channel compared to the previous quarter, contributing to a year-over-year revenue decline in the U.S.
Revenue DeclineDXCM's 2% U.S. revenue decline was significantly worse than expected, with price and mix challenges reaching an all-time high, suggesting it may take several quarters for growth to rebound.
---
Ownership Overview
0.41% Insiders
30.64% Mutual Funds
27.92% Other Institutional Investors
13.15% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $62.34 and its highest was $142.00 in the past 12 months.
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Feb 06, 2025 which is in 42 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 24, 2024. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.435 by $0.015.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is $0.52.
How many shares outstanding does Dexcom have?
Dexcom has 390,595,400 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.45 in its last earnings report, beating expectations of $0.435. Following the earnings report the stock price went down -1.884%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 692M.
---
Dexcom Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$98.94 (23.31% Upside)
$98.94 (23.31% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.32%
12-Months-Change
Fundamentals
Return on Equity
32.06%
Trailing 12-Months
Asset Growth
-3.67%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
DXCM Company Deck
---
DXCM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced outlook with significant achievements such as record new customer starts and international growth offset by challenges in the U.S. market, particularly in revenue and DME channel dynamics. The launch of Stelo and a strategic focus on the 15-day sensor submission demonstrate proactive steps towards future growth.Read More>---
DXCM Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$98.94
▲(23.31% Upside)
Technical Analysis
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
34/46 ratings generated profit
1 Year Average Return
+38.73%
assigned a buy rating 2 months ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 73.91% of your transactions generating a profit, with an average return of +38.73% per trade.
---